Literature DB >> 8209003

Importance of timing of radiotherapy in breast conserving treatment for early stage breast cancer.

B J Slotman1, O W Meyer, K H Njo, A B Karim.   

Abstract

This study reports on the treatment results in 508 patients with 514 AJCC stage I-II invasive breast carcinomas treated between July 1980 and July 1989. All patients underwent a lumpectomy with axillary lymph node dissection with postoperative irradiation. Adjuvant chemotherapy was given to premenopausal node-positive patients. Postmenopausal node-positive patients received adjuvant hormonal treatment. The median follow-up period was 68 months (range, 40-152 months). The 5-year survival rates were 92.6%, 81.4% and 65.5% for stage I, stage IIA and stage IIB, respectively. Distant metastases were the main cause of death. Locoregional failures occurred in 4.9%. Breast recurrences were detected in 17 patients (3.3%). In a Cox proportional hazards analysis, T-stage, pathological margins and interval between surgery and radiotherapy were identified as independent factors predictive of breast recurrence (p < 0.05). The results suggest that radiotherapy should be initiated early after surgery to maintain the breast recurrence rate as low as possible.

Entities:  

Mesh:

Year:  1994        PMID: 8209003     DOI: 10.1016/0167-8140(94)90459-6

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  8 in total

1.  Optimal sequence of implied modalities in the adjuvant setting of breast cancer treatment: an update on issues to consider.

Authors:  Pelagia G Tsoutsou; Yazid Belkacemi; Joseph Gligorov; Abraham Kuten; Hamouda Boussen; Nuran Bese; Michael I Koukourakis
Journal:  Oncologist       Date:  2010-11-01

2.  Current perceptions regarding surgical margin status after breast-conserving therapy: results of a survey.

Authors:  Alphonse Taghian; Majid Mohiuddin; Reshma Jagsi; Saveli Goldberg; Elizabeth Ceilley; Simon Powell
Journal:  Ann Surg       Date:  2005-04       Impact factor: 12.969

Review 3.  Recent developments in breast-conserving surgery for breast cancer patients.

Authors:  F Fitzal; O Riedl; R Jakesz
Journal:  Langenbecks Arch Surg       Date:  2008-09-10       Impact factor: 3.445

Review 4.  Surgical margins in head and neck squamous cell carcinoma: what is 'close'?

Authors:  Matteo Alicandri-Ciufelli; Marco Bonali; Alessia Piccinini; Laura Marra; Angelo Ghidini; Elio Maria Cunsolo; Antonino Maiorana; Livio Presutti; Pier Franco Conte
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-12-28       Impact factor: 2.503

5.  [Combined breast-preserving surgery, chemotherapy and radiotherapy in the treatment of breast carcinoma. Effect of the interval between surgery and the beginning of radiotherapy].

Authors:  H Willers; F Würschmidt; I Janik; H Bünemann; H P Heilmann
Journal:  Strahlenther Onkol       Date:  1997-03       Impact factor: 3.621

6.  Waiting time for radiation therapy in breast cancer patients in Quebec from 1992 to 1998: a study of surgically treated breast cancer patients in Quebec documents and helps to explain increased waiting times for radiation therapy.

Authors:  Bernard Fortin; Mark S Goldberg; Nancy E Mayo; Marie-France Valois; Susan C Scott; James Hanley
Journal:  Healthc Policy       Date:  2006-01

7.  A clip-based protocol for breast boost radiotherapy provides clear target visualisation and demonstrates significant volume reduction over time.

Authors:  Lorraine Lewis; Jennifer Cox; Marita Morgia; John Atyeo; Gillian Lamoury
Journal:  J Med Radiat Sci       Date:  2015-06-23

8.  Waiting time for radiation therapy after breast-conserving surgery in early breast cancer: a retrospective analysis of local relapse and distant metastases in 615 patients.

Authors:  Raffaella Caponio; Maria Paola Ciliberti; Giusi Graziano; Rocco Necchia; Giovanni Scognamillo; Antonio Pascali; Sabino Bonaduce; Anna Milella; Gabriele Matichecchia; Cristian Cristofaro; Davide Di Fatta; Pasquale Tamborra; Marco Lioce
Journal:  Eur J Med Res       Date:  2016-08-11       Impact factor: 2.175

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.